Isomorphic Labs
ShutdownIsomorphic Labs is an AI-first drug design and development company building a unified AI drug design engine (IsoDDE) to accelerate the discovery of novel therapeutics. The company's predictive and generative AI models, built on the foundation of AlphaFold, enable rapid identification and optimization of drug candidates across multiple therapeutic areas and drug modalities, including small molecules and biologics.
- Drug Discovery & Therapeutics
- Artificial Intelligence
- Biotechnology
Funding
Raised to date
$2.7BRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 3 rounds
AT+1$2.1B · Series B
Announced May 2026
Disclosed cumulative: $2.7B
Founders
Product
Problem
The traditional drug discovery and design process is lengthy and resource-intensive, often hindering the rapid development of treatments for severe diseases. This bottleneck delays the availability of novel therapies and limits the exploration of complex biological targets.
Solution
Isomorphic Labs is accelerating drug discovery by developing advanced artificial intelligence models. These predictive and generative AI systems are designed to unlock deeper scientific insights and expedite the design of novel therapeutic molecules. By leveraging AI, the company aims to significantly reduce the time and cost associated with bringing new medicines from concept to clinic. This approach is built upon foundational work in protein structure prediction, extending to a comprehensive engine for end-to-end drug design. The company's unified AI drug design engine (IsoDDE) works across multiple therapeutic areas and drug modalities, providing the predictive fidelity required to navigate novel biological systems with unprecedented accuracy.
Target Audience
Pharmaceutical companies, biotechnology firms, and research institutions seeking to enhance the efficiency and success rate of their drug discovery and development pipelines.
Features
- Predictive and generative AI models for accelerated drug discovery and design
- Proprietary unified drug design engine (IsoDDE) capable of addressing diverse therapeutic areas and drug modalities
- In silico capabilities for rapid identification and optimization of drug candidates, reducing reliance on extensive experimental wet-lab work
- Development of AI models that build upon and extend foundational breakthroughs like AlphaFold for protein structure and interaction prediction
- Focus on exploring novel chemical spaces and tackling historically challenging biological targets
- Integration of machine learning, computational chemistry, and biology expertise to create a comprehensive drug design pipeline
- Capability to design both small molecule therapeutics and biologics